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Abstract 
Background Low bioavailability of nitric oxide (NO) is implicated in the pathophysiology of 
sickle cell disease (SCD). We designed a nested pilot study to be conducted within a clinical 
trial testing the effects of a daily ready-to-use supplementary food (RUSF) fortified with 
arginine (Arg) and citrulline (Citr) vs. non-fortified RUSF in children with SCD. The pilot 
study evaluated 1) the feasibility of a non-invasive stable isotope method to measure whole-
body NO production and 2) whether Arg+Citr supplementation was associated with increased 
whole-body NO production. 
Subjects Twenty-nine children (70% male, 9-11years, weight 16.3-31.3kg) with SCD. 
Methods Sixteen children received RUSF+Arg/Citr (Arg, 0.2g/kg/day; Citr, 0.1g/kg/day) in 
combination with daily chloroquine (50mg) and thirteen received the base RUSF in 
combination with weekly chloroquine (150mg). Plasma amino acids were assessed using ion-
exchange elution (Biochrom-30, Biochrom, UK) and whole-body NO production was 
measured using a non-invasive stable isotopic method. 
Results The RUSF+Arg/Citr intervention increased plasma arginine (P=0.02) and ornithine 
(P=0.003) and decreased the ratio of asymmetric dimethylarginine to arginine (P=0.01), 
compared to the base RUSF. A significant increase in whole-body NO production was 
observed in the RUSF-Arg/Citr group compared to baseline (weight-adjusted systemic NO 
synthesis 3.38±2.29 µmol/kg/hr vs 2.35±1.13 µmol/kg/hr, P=0.04). No significant changes 
were detected in the base RUSF group (weight-adjusted systemic NO synthesis 2.64±1.14 
µmol/kg/hr vs 2.53±1.12 µmol/kg/hr, P=0.80). 
Conclusions The non-invasive stable isotopic method was acceptable and the results provided 
supporting evidence that Arg/Citr supplementation may increase systemic NO synthesis in 
children with SCD. 
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Introduction 
NO synthase (NOS) converts L-arginine into equimolar amount of NO and citrulline[1]. 
Citrulline is also a precursor for de novo renal arginine synthesis and, due to a slower hepatic 
clearance, citrulline supplementation may effectively increase systemic arginine 
concentrations [2]. A reduced nitric oxide (NO) bioavailability is thought to underlie vascular 
complications associated with Sickle Cell Disease (SCD)[3]. Arginine is metabolized by the 
arginase enzyme to ornithine which is a competitive inhibitor of arginine uptake by 
endothelial cells[4]. Clinical conditions associated with excessive haemolysis, such as SCD 
and malaria, are characterized by an excessive release of arginase from erythrocytes and 
consequent reduction of plasma arginine concentrations (i.e., hypo-argininemia) [2, 5, 6]. 
Stable isotopic methods used for the measurement of systemic whole-body NO synthesis are 
mostly based on the oral administration or intravenous infusion of labelled arginine and 
collection of repeated blood and urine samples [7]. Less invasive methods to measure NO 
availability are based on the measurement of NO metabolites in plasma (i.e., nitrite, nitrate, 
cGMP) but the validity and reproducibility of these biomarkers is limited as results may be 
confounded by factors such as dietary nitrate intake, kidney function or sensitivity of 
analytical methods[8]. Siervo et al. validated a non-invasive stable isotopic method to 
provide a quantitative and more accurate estimate of systemic whole-body NO synthesis in 
humans (Oral Nitrate Test, ONT)[9]. This method employs a very small oral dose of labelled 
sodium nitrate followed by the collection of repeated saliva samples over a period of 18 hours 
[9]. 
We conducted a pilot study to determine the feasibility of the ONT isotopic method to 
measure systemic NO synthesis in a sub-sample of Tanzanian children with SCD enrolled in 
the second phase of a random-order, double-blind, cross-over clinical trial (NCT01718054). 
A secondary objective was to determine whether daily supplementation with a ready-to-use-
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supplementary food (RUSF) fortified with arginine and citrulline [RUSF+Arg/Cit] increased 
systemic NO production compared to children receiving RUSF without Arg/Cit fortification. 
Methods 
Twenty-nine children (70% male, 9-11 years, weight 16.3-31.3kg) with SCD were enrolled in 
this study during the second intervention phase of the cross-over clinical trial. The study 
protocol was approved by the London School of Hygiene and Tropical Medicine and 
Muhimbili University of Health and Allied Sciences institutional review boards. All 
parents/guardians provided informed consent and all children assented. Sixteen children 
received RUSF+Arg/Cit (arginine, 0.2g/kg/day; citrulline, 0.1g/kg/day) in combination with  
daily chloroquine (50mg) and thirteen received the base RUSF in combination with weekly 
chloroquine (150mg). Both RUSF formulations provided 500 kcal, 1 RDA of vitamins and 
minerals & 1 mg of folate (Nutriset, France). The ONT method measures the decay of an oral 
dose of labeled sodium nitrate in serial saliva samples [9]. Briefly, children received a 
controlled low nitrate meal and a baseline saliva sample was collected 4 hours after the meal. 
This was followed by the ingestion of an oral dose of 4 mg of Na15NO3 (15N, 98% +, 
Cambridge Isotope Laboratories, Inc., Andover, MA, USA) in 100 mL of nitrate-free water. 
The remaining samples were collected at 6, 7, 8, 17 and 18 h post-meal. Measurements of 
nitrate enrichments in saliva were conducted using Gas Chromatography Mass Spectrometry 
as described by Siervo et al[9]. The isotopic decay of the oral dose of labelled nitrate was 
defined by an exponential function for a single compartment which was employed to 
calculate the rate of whole-body NO production[9]. Amino acid concentrations were 
measured in frozen lithium heparin plasma samples (Biochrom-30 amino acid analyzer 
(Biochrom, UK) at the end of each intervention period and at baseline entry into the main 
trial. More detailed descriptions of the ONT and amino acid analyses are provided in the 
online supplementary material. Whole-body NO production using the ONT method was 
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assessed at the end of each intervention phase after a mean duration of approximately 10.7 
weeks. NO production was assessed again after a washout period of approximately 8 weeks 
(range 5–12 weeks) in both intervention groups (Figure 1A). The sample size was calculated 
using data of NO production measured by the ONT method in obese subjects with and 
without metabolic syndrome (3). A sample size of nine subjects per group was estimated to 
have 90% power to detect a difference in whole-body NO production using the ONT method 
similar to that observed between obese adults with (0.21±0.13µmol/hr/kg) and without 
(0.49±0.22 µmol/hr/kg) metabolic syndrome [9].  
Mann-Whitney U test was used to assess significant differences in NO production between 
the RUSF+Arg/Cit and base RUSF intervention groups. The paired Wilcoxon test was used 
to assess significant changes in NO production between supplementation and wash-out 
periods within the same intervention group. Analyses were performed using SPSS 22 for 
Windows (IBM, USA). 
Results 
Age and sex were not associated with NO production (data not shown). The RUSF+Arg/Cit 
intervention significantly increased plasma arginine, ornithine, non-significantly increased 
citrulline and significantly decreased the ratio of asymmetric dimethylarginine (ADMA) to 
arginine compared to the base RUSF intervention. The global arginine bioavailability ratio 
(GABR; arginine/ornithine+citrulline) and the ratio of arginine to ornithine were not 
statistically different between the two interventions (Table 1). 
Baseline NO synthesis in children with SCD was 2.32±0.97µmol/kg/h. The difference in NO 
synthesis between the treatment and washout periods was significant in the RUSF-Arg/Citr 
group (P=0.04) but not in the RUSF group (P=0.80) (Figure 1B). The isotopic decay of the 
stable isotope tracer was characterized by a good linear fit in both groups; the effect of the 
interventions on systemic NO production is described by the differences in isotopic decays in 
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the RUSF (Figure 1C) and RUSF+ARG/CIT (Figure 1D) groups. However, the difference in 
NO synthesis between the RUSF-Arg/Citr and RUSF groups at the end of the intervention 
was not significant (P=0.31). NO synthesis was not correlated with citrulline, arginine and 
ADMA concentrations, and ADMA to arginine ratio (data not shown). 
Discussion 
The acceptability of the ONT method in children with SCD was good. This is the first study 
to report measurements of systemic NO production in non-hospitalised children with SCD 
using a non-invasive stable isotopic method, which may promote further research into the 
role of NO in SCD and other conditions characterized by impaired NO regulation. Baseline 
NO synthesis rates in children with SCD (2.32±0.97µmol/kg/h) were greater than healthy 
adults (0.63±0.20 µmol/kg/h) and obese subjects with metabolic syndrome (0.21±0.13 
µmol/kg/h) using the ONT method[9]. The NO synthesis rates observed in our study were 
also greater than rates measured in hospitalized children with uncomplicated malaria using an 
invasive method requiring an intravenous administration of labelled 15N-arginine (0.83±0.11 
µmol/kg/h; range 0.3-2.65 µmol/kg/h) and collection of total urine output over a period of 48 
hours [10]. A lower systemic NO synthesis was also measured in ten critically ill children 
with sepsis (NO synthesis rate = 1.58±0.7 µmol/kg/h) and differences with our study could be 
related to disease pathogenesis and/or characteristics of the stable isotope methods[11]. 
However, two studies found similar (2.4±0.6 µmol/kg/h)[12] or higher (4.3±2.7 
µmol/kg/h)[13] NO synthesis rates in adult patients with cirrhosis and end stage renal 
disease, respectively, using isotopic methods based on the intravenous administration of 
labelled arginine. There is currently limited information on the NO synthesis rates in pediatric 
populations. The only study to evaluate the efficiency of the enzymatic NO synthetic pathway 
in children was conducted by Forte et al [14]. The study used oral labelled arginine in 17 
healthy children aged 4 to 16 years old to measure the percentage of L-[15N]2-guanidino 
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arginine dose directed to NO synthesis but it did not report rates of  whole-body NO 
synthesis. The study found that the proportion of labelled arginine directed  to  NO  synthesis  
was  0.22% and also observed that the percent rate of incorporation was inversely associated 
with age (r=-0.53, p<0.05); we did not observe a similar association  between age and NO 
synthesis which could be due to the narrower age range of our population. 
A previous study has shown that oral supplementation with arginine and citrulline increases 
NO synthesis in patients with SCD [15, 16] and improves NO-mediated endothelial function 
in adults with impaired vascular health[17]. The higher NO synthesis observed in our study 
suggest that NO synthesis in children with SCD may not be affected by a reduced availability 
of arginine and the elevated rate of whole-body NO synthesis may be the result of 
compensatory responses to an increased NO degradation[18, 19].  
However, this study is characterized by several limitations which need to be taken into 
account in the interpretation of the results. Systemic NO production measured by the ONT 
method reflects the contribution of both enzymatic and non-enzymatic NO synthetic 
pathways; however, the controlled low nitrate diet followed by the children as part of the 
ONT protocol was implemented to reduce the contribution of the non-enzymatic 
pathway[20]. In addition, there is currently no evidence on the effects of arginine, citrulline 
and nitrate supplementation on the efficiency of bacterial and tissue nitrate reductase activity 
and therefore the impact of these nutrients and drug on the rate of conversion of nitrate into 
NO via the non-enzymatic synthetic pathways is undetermined. It is also important to 
highlight that an increase in NO synthesis and overall bio-availability does not necessarily 
correspond to an increased NO-mediated activation of cellular mechanisms. It is possible that 
the observed increase in systemic NO production in the RUSF-Arg/Cit group was the result 
of the higher dose of chloroquine in this group, rather than from a greater supply of arginine 
from the fortificants, which may have reduced arginase activity [21] and/or inflammation[22, 
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23] and result in greater NO bioavailability in children with SCD[24]. However, there was no 
difference in the arginine:ornithine ratio between the two groups and therefore a different 
degree of inhibition of arginase activity by chloroquine administration seems unlikely. In 
addition, weekly doses of chloroquine in the RUSF group did not have an effect on NO 
synthesis. While we found a decrease in the ADMA to arginine ratio between the two 
intervention groups, the within-intervention changes of the ratio were not different between 
the two groups, which, if added to a lack of significant correlation of the ADMA to arginine 
ratio with whole-body NO production, seems to suggest that ADMA was not linked to the 
increase in NO synthesis. Finally, a comparison of systemic NO production rates measured in 
children with SCD and age-matched healthy controls should be investigated in future studies.  
The application of the non-invasive isotopic method for the measurement of systemic NO 
production is feasible in this population and our results suggest that supplementation with 
arginine and citrulline may increase NO synthesis in children with SCD, although it is 
unclear by what mechanism. 
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Table 1: Age, sex, weight and plasma amino acid concentrations involved in nitric oxide synthesis in 
the two groups of children during intervention either with RUSF+ARG/CIT or standard RUSF 
 RUSF+ARG/CITR RUSF P* 
N 16 13  
Age (years) 11.06±1.23 11.30±1.25 0.68 
Gender (M/F) 13/3 7/6 0.11 
Weight (kg) 24.61±3.52 25.18±3.43 0.75 
Arginine (nmol/mL) 130.16±115.65 62.11±15.58 0.02 
Ornithine (nmol/mL) 101.05±71.00 52.33±12.81 0.003 
Citrulline (nmol/mL) 48.19±62.66 22.18±6.02 0.07 
ADMA (nmol/mL) 0.95±0.25 0.96±0.24 0.84 
Arginine/Ornithine Ratio 1.22±0.35 1.20±0.23 0.89 
ADMA/Arginine Ratio 0.011±0.007 0.016±0.006 0.01 
GABR 0.86±0.23 0.84±0.17 0.49 
Data are presented as mean±SD. N= number of subjects; M= Male; F= Female. ADMA= asymmetric dimethylarginine. RUSF= 
ready-to-use supplementary food. ARG= arginine; CITR= citrulline; GABR=Global arginine bioavailability ratio.  Mann-
Whitney test was used to compare the two intervention groups. *P value is for comparison of the two intervention groups 
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Figure Legends 
Figure 1A: Study design. Figure summarises the oral nitrate test (ONT) method used to measure nitric 
oxide synthesis and the time points of sample collection from children in the 2nd phase of the V-FIT cross-
over trial. Figure 1B Differences in whole body NO synthesis measured using the ONT between 
supplemented (RUSF+Arg/Citr in combination with daily chloroquine [50mg]) and non-supplemented 
arms (base RUSF in combination with weekly chloroquine [150mg]) during the intervention and wash out 
period. Data presented as mean±SEMs and P-values from paired Wilcoxan tests for non-parametric data. 
Figure 1C & 1D show the time-course of the isotopic disappearance of the tracer, expressed as tracer-
tracee ratio, followed for 14 hours after the administration of an oral dose of labeled sodium nitrate 
(Na15NO3). The mean values of the tracer-tracee ratio for the saliva kinetic curves are reported on a semi-
logarithmic scale and shown for the base RUSF (Figure 1C) and RUSF+Arg/Citr (Figure 1D) arms. 
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Highlights 
 
 
• This method for measuring whole-body NO synthesis is feasible in young children  
• The isotopic decay of the stable isotope tracer demonstrated good linear fit 
• Arginine and citrulline supplementation may increase whole-body NO synthesis  
